Real-World Application of PD-1 Inhibitors in High-Grade Glioma: A Case Series.
- 1Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
Abstract
Background/Objectives: Patients with high-grade glioma (HGG) have a poor prognosis despite maximal safe resection, radiotherapy, and chemotherapy, partly because of the immunosuppressive tumor microenvironment. Unfortunately, all phase III trials of anti-PD-1 therapy to date have failed to yield positive results in HGGs. Recent early-phase trials have identified promising strategies involving immune checkpoint inhibitors. Here, we share our 8-year experience with anti-PD-1 therapy in patients with HGG in a real-world setting. Methods: All patients with HGG who received PD-1 inhibitor-based therapy at our center between 2018 and 2026 were included. Medical records were reviewed longitudinally for each patient, and the latest follow-up data were collected. Patients lost to follow-up were excluded. Results: Four regimens involving anti-PD-1 treatment were identified in 22 patients with HGG (newly diagnosed = 11, recurrent = 11): (1) VEGFR-targeted therapy plus PD-1 inhibition (9 recurrent HGGs), (2) the "2-THE-TOP" regimen (tumor-treating fields plus temozolomide and PD-1 inhibitor therapy) (5 newly diagnosed HGGs), (3) anti-PD-1 monotherapy (2 recurrent and 2 newly diagnosed HGGs), and (4) neoadjuvant plus adjuvant anti-PD-1 therapy (4 newly diagnosed HGGs). Median overall survival for these four regimens was 32.7, 20.3, 28.6, and 31.8 months, respectively. No grade 3-4 treatment-related adverse events were recorded. Conclusions: Our preliminary observations suggest that PD-1 blockade may remain a viable option for patients with HGG when combined with specific therapies, administered with careful timing, and applied in selected patients.
Related
- Prognostic Value of Systemic Inflammation Markers and Clinical Factors in Grade 4 Diffuse Glioma: A Multicenter Retrospective Real-World Study.
- Case Report: Case series: growth hormone replacement for severe growth hormone deficiency during BRAF inhibitor therapy in pediatric low-grade glioma: long-term follow-up
- The Efficacy and Safety of Adding Teniposide to Temozolomide Plus Bevacizumab in Recurrent Grade 4 Glioma: A Real-World Exploratory Single-Center Study
- Evaluation of boundary-aware UNet++ for low-grade glioma segmentation
- Atlas-Based MRI Spatial Phenotyping in Pediatric Low-Grade Glioma
BibTeX
@article{ren2026realworld,
title = {{Real-World Application of PD-1 Inhibitors in High-Grade Glioma: A Case Series.}},
author = {Yin Ren and Xiaopeng Guo and Hao Xing and Xiaoman Kang and Tingyu Liang and Yixin Shi and Bohan Yao and Wenbin Ma and Yu Wang},
journal = {Cancers},
year = {2026},
month = sep,
doi = {10.3390/cancers18193122},
url = {https://europepmc.org/article/MED/42882817},
note = {CC BY},
}
RIS
TY - JOUR
TI - Real-World Application of PD-1 Inhibitors in High-Grade Glioma: A Case Series.
AU - Yin Ren
AU - Xiaopeng Guo
AU - Hao Xing
AU - Xiaoman Kang
AU - Tingyu Liang
AU - Yixin Shi
AU - Bohan Yao
AU - Wenbin Ma
AU - Yu Wang
PY - 2026
DA - 2026/09/26
JO - Cancers
DO - 10.3390/cancers18193122
UR - https://europepmc.org/article/MED/42882817
AB - Background/Objectives: Patients with high-grade glioma (HGG) have a poor prognosis despite maximal safe resection, radiotherapy, and chemotherapy, partly because of the immunosuppressive tumor microenvironment. Unfortunately, all phase III trials of anti-PD-1 therapy to date have failed to yield positive results in HGGs. Recent early-phase trials have identified promising strategies involving immune checkpoint inhibitors. Here, we share our 8-year experience with anti-PD-1 therapy in patients with HGG in a real-world setting. Methods: All patients with HGG who received PD-1 inhibitor-based therapy at our center between 2018 and 2026 were included. Medical records were reviewed longitudinally for each patient, and the latest follow-up data were collected. Patients lost to follow-up were excluded. Results: Four regimens involving anti-PD-1 treatment were identified in 22 patients with HGG (newly diagnosed = 11, recurrent = 11): (1) VEGFR-targeted therapy plus PD-1 inhibition (9 recurrent HGGs), (2) the "2-THE-TOP" regimen (tumor-treating fields plus temozolomide and PD-1 inhibitor therapy) (5 newly diagnosed HGGs), (3) anti-PD-1 monotherapy (2 recurrent and 2 newly diagnosed HGGs), and (4) neoadjuvant plus adjuvant anti-PD-1 therapy (4 newly diagnosed HGGs). Median overall survival for these four regimens was 32.7, 20.3, 28.6, and 31.8 months, respectively. No grade 3-4 treatment-related adverse events were recorded. Conclusions: Our preliminary observations suggest that PD-1 blockade may remain a viable option for patients with HGG when combined with specific therapies, administered with careful timing, and applied in selected patients.
SN - 2072-6694
ER -